Evotec SE (NASDAQ:EVO) is one of the 8 Best Life Sciences Penny Stocks to Buy.
On March 10, Evotec SE (NASDAQ:EVO) announced Horizon, the follow-up phase in its multi-stage transformation initiative. The Horizon operating model embodies its evolution in the adoption of a new, focused operating model that comprises three elements, i.e., operation, science, and commercial execution.
everything possible/Shutterstock.com
This new Horizon operating model is aimed at delivering above-market growth and leveraging operations in an environment of normalized demand expectations. Moreover, it will ensure higher standards of scientific and operational performance based on the Priority Reset in 2024 and the mid-term value creation approaches outlined in 2025.
Horizon will streamline its corporate structure, with the realignment of Evotec’s worldwide experience through Centers of Excellence, as well as the appropriate positioning of Evotec’s footprint. The plan envisages optimization of the company’s footprint from 19 locations in 2024 to 14 locations in 2025 to 10 locations within the next two years. This process will be complemented by workforce restructuring up to 800 positions.
According to Evotec CEO Dr. Christian Wojczewski, Horizon marks the next stage in Evotec’s structured transformation journey, enabling the organization to become ready for sustainable, high-quality growth. He stated:
“Horizon represents the next step in Evotec’s structured transformation to position the company for sustainable, high-quality growth. Following the disciplined cost actions implemented over the past two years and the strategic priorities we set in 2025, we are now transforming our operating model. This will enable deeper integration, faster decision making and greater agility for our customers and partners. Horizon positions Evotec for stronger performance through 2027 and lays the foundation for further optimization and intelligent scaling toward 2030.”
Evotec SE (NASDAQ:EVO) is engaged in the research and development of therapeutics. The company offers pharmaceutical products for various healthcare sectors, including oncology, autoimmune, and respiratory, to name a few. It has collaboration agreements with several hospitals and universities, including Mass General Brigham, Harvard, Yale, and more.
While we acknowledge the risk and potential of EVO as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than EVO and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. Follow Insider Monkey on Google News.
